

## APPENDIX G: accompaniment to preventive care checklist for transmasculine patients

### EXPLANATIONS FOR TRANS-SPECIFIC RECOMMENDATIONS

Note: This form has been adapted with permission from Dr. V. Dubey from the CFPC-endorsed Preventive Care Checklist Form©. The use of these trans-specific forms assumes familiarity with the original forms and their explanations. The original form contains graded evidence-based recommendations,<sup>1</sup> which may or may not be applicable to transgender patients. Unbolded recommendations should be followed as per the original forms. The specific recommendations herein represent an effort to incorporate expert opinion and limited trans-specific evidence with standard National and Provincial primary care practices in a practical format that can be accessed at the point-of-care

### MEDICAL TRANSITION HISTORY

Establishment of a patient's status regarding gender-related treatments and timing of these treatments at the outset of a preventive care assessment allows for patient-centred tailoring of counselling, education, physical examination, and screening recommendations

### LIFESTYLE/HABITS/PSYCHOSOCIAL

An effort should be made to assess the impact of transition/transgender identity, experiences of transphobia and impact on employment, housing, family, relationships, and economic well-being

**Social Supports** – specific attention should be given to assessing the extent of a patient's social supports, creating an opportunity to suggest additional resources if needed

**Sexual History** – delineating the types of sex that the patient is having and with whom will direct the indicated type and frequency of STI screening

**Family Planning/Contraception** – transmasculine patients considering hormonal treatment and/or gonadectomy should be counselled regarding the option for fertility preservation (see [Guidelines for gender-affirming primary care with trans and non-binary patients, Part I - Fertility and Birth Control](#), and RHO's [Reproductive Options Fact Sheet](#) and the LGBTQ Parenting Network's '[Fertility Preservation for People Who Produce Sperm](#)'<sup>2</sup>)

See also potential for pregnancy/need for birth control below.

**Name change/identification** – assess patient need/desire to change name and/or sex marker on identification and offer support for this process (see [Guidelines for gender-affirming primary care with trans and non-binary patients, Part I - Changing Sex Designation on Government ID](#), and [Appendices Q and R](#))

**Alcohol** – due to presumed smaller liver size compared with cis men, we suggest that transmasculine patients, regardless of exogenous hormone use, follow the safe-drinking guidelines for cis women (i.e. maximum 10 drinks a week with no more than 2 drinks a day most days, see [Canada's Low-risk Alcohol Drinking Guidelines](#))<sup>3</sup>

**Sleep** – testosterone therapy may worsen or unmask obstructive sleep apnea,<sup>4</sup> consider inquiring re: symptoms of sleep apnea; in those with sleep apnea, CPAP requirements may change with masculinizing hormone therapy and should be monitored

## FUNCTIONAL INQUIRY

An effort should be made to use language consistent with a patient's gender identity; if unsure, consider asking the patient how they refer to their body parts

**Mental Health** – inquire re: experiences and impacts of transphobia; screen for mood disturbances including irritability, anger, and depression, as well as anxiety (particularly social anxiety) and self-harm; suicidal ideation and attempts are particularly high in the trans population<sup>5</sup> and should be specifically inquired about; inquire regarding symptoms of hypomania, mania, or psychotic symptoms in patients on testosterone who have underlying psychiatric disorders that include such symptoms; inquire re: current level of gender dysphoria and body image, (re-)assess patient interest in transition related surgeries if not undergone

**Chest** – inquire regarding skin changes, lumps/bumps and nipple discharge regardless of surgical status, if patient has undergone chest reconstruction, consider asking about scarring and patient satisfaction with surgical outcome (in some cases, revisions can be considered to optimize cosmetic appearance); if patient has not undergone chest reconstruction consider asking about binding (the practice of compressing chest tissue to create a flatter appearance) and any associated MSK, dermatologic, or respiratory symptoms; encourage the use of a product designed specifically for the purpose of chest binding (several commercial brands are available, for a comparison see '[Chest Binding 101](#)')<sup>6</sup> and discourage the use of other products such as tensors or duct tape; binding frequency (#days/week), and to a lesser extent binding intensity (#hours/day) have been found to be positively correlated with negative effects, suggesting that 'days off' and/or shortened duration of binding may minimize complications);<sup>7</sup> most manufactures recommend maximum use of 8 hours per day. Some private insurance companies will cover the cost of a commercial binder as a medical device with a prescription.

**GU/PV Bleeding** – inquire about symptoms of vaginal atrophy (if on testosterone), vaginal bleeding, discharge, and pelvic pain. Problematic symptoms due to vaginal atrophy often respond to topical estrogen; pelvic pain may be associated with cyclic testosterone dosing – changing the frequency/route of testosterone and/or the use of NSAIDs can be helpful (see *Guidelines for gender-affirming primary care with trans and non-binary patients, Part III - Pelvic Pain*)

**NB:** any unexplained vaginal bleeding once full menstrual cessation has been achieved on testosterone warrants a full work-up for endometrial hyperplasia/malignancy

**Sexual Function** – inquire regarding libido/hypersexual behaviour, dyspareunia (as indicated by surgical status and sexual activity), and post-orgasmic uterine cramping

**Derm** – inquire re: acne and androgenic alopecia, both of which may be managed as in cis patients

## EDUCATION/COUNSELLING

**Adequate Calcium Intake** – all transmasculine patients on testosterone should ensure a minimum intake of 1200 mg of Calcium daily (diet + supplements)

**Adequate Vitamin D** – all transmasculine patients on testosterone should take 1000 IU of vitamin D daily

**Hormone Adherence** – missed doses of testosterone may impact bone health if post-oophorectomy, while extra doses may lead to a host of problems associated with supratherapeutic testosterone levels

**Regular, moderate physical activity** – weight-bearing exercise helps in osteoporosis prevention; to avoid tendon rupture in transmasculine individuals on testosterone weight loads used in strength training should be increased gradually with an emphasis on repetitions and stretching

**Safe sex practices/STI counselling** – transmasculine patients may be at high risk of STIs depending on behavioural factors; inquire re: sexual practices and risks including sex work; safer sex counselling, frequent screening (i.e. every 3 months) and an assessment of indications for HIV PrEP<sup>8</sup> are indicated for those at high risk. For patient-centred handout materials, see [PRIMED<sup>2</sup>: A Sex Guide for Trans Men into Men](#)<sup>9</sup>

**Potential for pregnancy/need for birth control** – transmasculine patients on testosterone (who have not undergone hysterectomy) may become pregnant even if menstrual suppression has been achieved and should be counselled in this regard; given that testosterone is a teratogen, reliable birth control should be instituted where pregnancy is a risk based on sexual activity; signs and symptoms of pregnancy can be reviewed, as well as options and resources should unplanned pregnancy occur

**Need for folic acid** – transmasculine patients not on testosterone and in whom pregnancy is possible based on sexual activity, as well as for those who are hoping to achieve pregnancy, folic acid recommendations are the same as for cis women

**Overweight/Obese** – screen for mental health contributors – persistent gender dysphoria may be associated with a desire to maintain a larger body habitus in order to hide indicators of sex assigned at birth, which may have negative health impacts; strategizing around other ways to address persistent gender dysphoria may be helpful; barriers to physical activity can also include an avoidance of gyms/locker rooms which the provider may help strategize around; screening for eating disorders is also warranted (see below)

**Underweight** – eating disorders are more common in LGBT2SQ populations, particularly amongst youth; screening is warranted in those presenting with BMI<18 or other related signs/symptoms

**Smoking** – tobacco use can worsen polycythemia (Hb/Hct above male range) which can be associated

with testosterone administration, and increases the risk of CVD and thromboembolic events

**Alcohol and other substances** – substance use is more prevalent in members of the LGBT2SQ community; inquire re: problematic use of substances including testosterone without a prescription and anabolic steroids; if referral to substance abuse program is indicated, consider an LGBT2SQ-specific or LGBT2SQ-positive program such as [Rainbow Services at CAMH](#). Offer safer smoking and injection kits when indicated for harm reduction. A naloxone kit and instructions on use should be offered to all patients who are at risk of opioid overdose, as well as friends and family of those at risk<sup>10</sup>

**Advanced care planning** – A discussion regarding advanced care planning is recommended at least once for Canadians  $\geq 65$ .<sup>11</sup> Trans and gender diverse patients may have particular needs in ensuring that their gender identity and expression are respected and a respectful decision-maker is chosen ([See Creating End of Life Documents for Trans Individuals: An Advocate's Guide](#))<sup>12</sup>

**Injection safety** – for patients who self-inject testosterone: confirm dose, review aseptic injection technique, inquire re: rotating injection sites, injection site reactions, and pre-injection anxiety; consider conversation re: SC vs. IM injection vs. transdermal route options, ensure safe sharps disposal

**Bathroom safety** – finding a bathroom that feels comfortable and safe can frequently be a source of stress for trans individuals. Resources such as [Refuge Restrooms](#)<sup>13</sup> can assist trans people in locating gender neutral bathrooms

## PHYSICAL EXAMINATION

**Chest** – testosterone therapy is not thought to increase the risk of breast cancer; for transmasculine individuals who have not undergone chest reconstruction, clinical chest (i.e. breast) exam

is of questionable utility but can be considered according to a provider's common practice with cis women; transmasculine individuals who have undergone chest reconstruction are at low risk and chest and axillary lymph node exam are of questionable utility but may be considered to assess for abnormalities in the remaining breast tissue; if an abnormality is noted in this case, ultrasound +/- MRI is indicated as mammography is technically difficult or may be impossible

**Pelvic/Pap** – follow cervical cancer screening guidelines as for cis women if the cervix is present; there is no evidence to support the performance of a bimanual exam but if uterus and/or ovaries are present this can be considered according to the clinician's routine practice with cis women, and may be helpful in determining the appropriate width/length of speculum to use; several strategies may be employed to minimize the discomfort/trauma associated with speculum examination for some transmasculine individuals ([see Tips for Providing Paps to Trans men](#)).<sup>14</sup> Barring contraindications, topical 2% lidocaine jelly may be applied vaginally 5-10 minutes prior to the procedure in those who find speculum examination painful due to atrophic changes. The pre-procedural administration of low-dose lorazepam or the use of vaginal estrogens for 1 week prior to the exam may also be helpful

**Ano-rectum** – for those who engage in receptive anal sex, visual examination of the perianal region for any evidence of anal warts or other anorectal problems such as hemorrhoids should be considered; particularly those who are HIV+. Additionally consider DRE for detection of internal lesions. HIV+ patients with physical findings consistent with warts or other HPV-related changes should also be referred for HRA

**Derm** – examine for acne and androgenic alopecia

## LABS/INVESTIGATIONS

**Mammography** – for transmasculine patients who have not undergone chest reconstruction, follow guidelines as for cis women; mammography is not required following chest reconstruction; for all transmasculine patients, if a strong family history of breast cancer is present, follow the same guidelines as for cis women regarding indications for referral to a high risk screening program/genetic assessment

**GC/CT/Syphilis/HIV/HBV/HCV screen** – consider STI detection from the following sites as indicated: throat, urethra, vagina, ano-rectum, and serum. NB: Self-collected frontal (vaginal) swabs may be more sensitive for diagnosing GC and CT than provider-collected swabs and first-catch urine<sup>15</sup> and may help minimize discomfort for trans patients

**Cervical cytology** – see Pelvic/Pap above, if patient is on testosterone, ensure to note this on the cytology requisition in order to minimize histological misinterpretation; inadequate samples are more common in patients on testosterone and repeat may be required - the use of both brush and broom may increase yield in patients with atrophic changes<sup>16</sup>

**Yearly trans bloodwork** – yearly investigations listed are for those currently on testosterone; bloodwork should be tailored to the patient's hormone regimen, risk factors and pre-existing conditions; screening for DMII and dyslipidemia should be performed at baseline and 1 year following hormone therapy initiation; and otherwise according to routine guidelines for cis patients. Framingham calculation will be less reliable with exogenous hormone use - depending on the age of hormone initiation and duration of hormone exposure providers may choose to use the risk calculator for sex assigned at birth, affirmed gender, or an average of both.<sup>17</sup>

**Note:** For patients on testosterone male reference ranges should be used for Hb/Hct, however the lower limit of the female range can be used if menstruating

**BMD** – there is no evidence to suggest that testosterone therapy negatively impacts BMD; in accordance with national recommendations, perform bone mineral density testing in all transmasculine patients over age 65

BMD should be considered earlier in those at high risk, such as those who, for a significant period of time (i.e. >2 yrs):

- have been on low-dose or no hormones and are agonadal
- have been on a GnRH analogue without exogenous estrogen

BMD testing may additionally be considered in agonadal transmasculine patients with elevated LH.<sup>18</sup> (See ‘[Part III Osteoporosis and BMD Screening](#)’)

**Note:** frequency of BMD screening will depend on the results of the initial scan

**Anal Pap screening** – for those who have a history of receptive anal sex, consider anal pap every 2-3 years or yearly in those who are HIV+ (if local HRA for the follow up of abnormal results is available). See the Canadian Cancer Society’s [Colon cancer screening guidelines for gay and bisexual men](#) for more information

## IMMUNIZATIONS

**Hepatitis A/Hepatitis B** – transmasculine patients may be at higher risk of Hep A/B depending on behavioural risks, trans MSM qualify for publicly funded vaccination

**HPV** – consider HPV vaccination in transmasculine patients up to age 45; publicly covered ≤26 yrs if sexually active with MSM

CFPC – College of Family Physicians of Canada,  
STI – sexually transmitted infection,  
RHO – Rainbow Health Ontario,  
CPAP – continuous positive airway pressure,  
MSK – musculoskeletal,  
GU – genitourinary,  
PV – per vagina,  
NSAIDs – non-steroidal anti-inflammatories,  
IU – international units,  
Hb - Hemoglobin,  
Hct - Hematocrit,  
LGBT2SQ – lesbian, gay, bisexual, trans, queer, and two-spirit,  
BMI – body mass index,  
CVD – cardiovascular disease,  
CAMH – Centre for Addiction and Mental Health ,  
MRI – magnetic resonance imaging,  
DRE - digital rectal exam, HRA - high resolution anoscopy,  
HIV – human immunodeficiency virus,  
GC – gonococcus,  
CT – chlamydia trachomatis,  
HBV – Hepatitis B virus, HCV – Hepatitis C virus,  
DMII - diabetes mellitus type II,  
Hb - hemoglobin, Hct - hematocrit,  
BMD – bone mineral density,  
LH – luteinizing hormone,  
MSM – men who have sex with men,  
HPV – human papillomavirus,  
MSM - men who have sex with men

1. Ridley J, Ischayek A, Dubey V, Iglar K. Adult health checkup: Update on the Preventive Care Checklist Form©. Can Fam Physician Med Fam Can. 2016; 62(4):307–13.22. RHO Fact Sheet: Reproductive options for trans people [Internet]. Toronto: Rainbow Health Ontario; 2012 p. 9. Available from: [https://www.rainbowhealthontario.ca/wp-content/uploads/woocommerce\\_uploads/2012/09/RHO\\_FactSheet\\_REPRODUCTIVEOPTIONSFORTRANSPeople\\_E.pdf](https://www.rainbowhealthontario.ca/wp-content/uploads/woocommerce_uploads/2012/09/RHO_FactSheet_REPRODUCTIVEOPTIONSFORTRANSPeople_E.pdf)
2. LGBTQ Parenting Network [Internet]. Toronto: Sherbourne Health; [updated 2018]. Fertility preservation for trans people who produce sperm; [2018] [cited 2019 Feb 8]. Available from:
3. The Canadian Centre on Substance Use and Addiction [Internet]. Ottawa: The Canadian Centre on Substance Use and Addiction; [updated 2018]. Canada’s low risk alcohol drinking guidelines; [2012] [cited 2019 Feb 7]. Available from: <http://www.ccsa.ca/Resource%20Library/2012-Canada-Low-Risk-Alcohol-Drinking-Guidelines-Brochure-en.pdf>
4. Matsumoto AM, Sandblom RE, Schoene RB, Lee KA, Giblin EC, Pierson DJ, et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (Oxf). 1985; 22(6):713–21..
5. Bauer G, Pyne J, Francino M, Hammond R. La Suicidabilité parmi les personnes trans en Ontario : Implications en travail social et en justice sociale. Serv Soc. 2013; 59(1):35–62.
6. [TransGuys.com](#); [updated 2019]. Chest Binding 101 - FTM - Updated for 2017; [2010] [cited 2019 Feb 7]. Available from: <https://transguys.com/features/chest-binding>
7. Peitzmeier S, Gardner I, Weinand J, Corbet A, Acevedo K. Health impact of chest binding among transgender adults: a community-engaged, cross-sectional study. Culture, Health & Sexuality 2017;19(1):64-75
8. Tan DHS, Hull MW, Yoong D, Tremblay C, O’Byrne P, Thomas R, et al. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ. 2017; 189(47):E1448–58.
9. PRIMED2: A sex guide for trans men into men [Internet]. Toronto: CATIE; 2015. Available from: <http://librarypdf.catie.ca/PDF/ATI-20000s/24654.pdf>
10. Ontario Ministry of Health and Long-Term Care [Internet]. Toronto: Ontario Ministry of Health and Long-Term Care [updated 2018]. Naloxone - Drugs and Devices; [date unknown] [cited 2019 Feb 8]. Available from: <http://www.health.gov.on.ca/en/pro/programs/drugs/naloxone/>

11. Speak Up [Internet]. Ottawa: Canadian Hospice Palliative Care Association; [updated 2019] [cited 2019 Feb 7]. Available from: <http://www.advancecareplanning.ca/>
12. National Resource Center on LGBT Aging [Internet]. New York: National Resource Center on LGBT Aging; [updated 2019]. Creating end-of-life documents for trans individuals: An advocate's guide; [October 2014] [cited 2019 Feb 7]. Available from: <https://www.lgbtagingcenter.org/resources/resource.cfm?r=694>
13. REFUGE Restrooms [Internet]. REFUGE Restrooms; [updated 2019] [cited 2019 Feb 7]. Available from: <https://www.refugerestrooms.org/about>
14. Potter, M. Rainbow Health Ontario [Internet] Toronto: Rainbow Health Ontario; [updated 2018]. Tips for providing paps to trans men; [updated 2015] [cited 2019 Feb 4]. Available from: <https://www.rainbowhealthontario.ca/resources/tips-for-providing-paps-to-trans-men>
15. Korownyk C, Kraut RY, Kolber MR. Vaginal self-swabs for chlamydia and gonorrhea. *Can Fam Physician*. 2018; 64(6):448.
16. Davis-Devine S, Day SJ, Anderson A, French A, Madison-Henness D, Mohar N, et al. Collection of the BD SurePath Pap Test with a broom device plus endocervical brush improves disease detection when compared to the broom device alone or the spatula plus endocervical brush combination. *CytoJournal*. 2008; 6:4.
17. Deutsch M. Centre of Excellence for Transgender Health [Internet]. San Francisco: University of California; [updated 2019]. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people; 2016 [cited 2019 Jan 31]. Available from <http://transhealth.ucsf.edu/trans?page=guidelines-home>
18. van Kesteren P, Lips P, Gooren LJ, Asscheman H, Megens J. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. *Clin Endocrinol (Oxf)*. 1998; 48(3):347–54.